Compare PAXS & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PAXS | YDES |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 664.0M | 543.0M |
| IPO Year | 2021 | 2024 |
| Metric | PAXS | YDES |
|---|---|---|
| Price | $13.26 | $7.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 281.0K | ★ 663.5K |
| Earning Date | 01-01-0001 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.92 | $1.70 |
| 52 Week High | $16.56 | $22.00 |
| Indicator | PAXS | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 71.98 |
| Support Level | $12.92 | $2.33 |
| Resistance Level | $14.85 | $9.11 |
| Average True Range (ATR) | 0.19 | 0.89 |
| MACD | 0.00 | 0.43 |
| Stochastic Oscillator | 42.31 | 87.02 |
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.